Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

HER3 inhibitor

DRUG CLASS:

HER3 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

NRG1 fusion	Non Small Cell Lung Cancer	NRG1 fusion	Non Small Cell Lung Cancer	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1
NRG1 fusion	Pancreatic Ductal Adenocarcinoma	NRG1 fusion	Pancreatic Ductal Adenocarcinoma	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1	zenocutuzumab-zbco Sensitive: A1 - Approval zenocutuzumab-zbco Sensitive : A1
NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	MM-121 Sensitive: B - Late Trials MM-121 Sensitive : B	MM-121 Sensitive: B - Late Trials MM-121 Sensitive : B
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Cholangiocarcinoma	NRG1 fusion	Cholangiocarcinoma	zenocutuzumab-zbco Sensitive: C1 - Off-label zenocutuzumab-zbco Sensitive : C1	zenocutuzumab-zbco Sensitive: C1 - Off-label zenocutuzumab-zbco Sensitive : C1
NRG1 fusion	Breast Cancer	NRG1 fusion	Breast Cancer	zenocutuzumab-zbco Sensitive: C1 - Off-label zenocutuzumab-zbco Sensitive : C1	zenocutuzumab-zbco Sensitive: C1 - Off-label zenocutuzumab-zbco Sensitive : C1
NRG1 fusion	Lung Cancer	NRG1 fusion	Lung Cancer	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2
NRG1 fusion	Ovarian Cancer	NRG1 fusion	Ovarian Cancer	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	SI-B001 Sensitive: C2 – Inclusion Criteria SI-B001 Sensitive : C2	SI-B001 Sensitive: C2 – Inclusion Criteria SI-B001 Sensitive : C2
NRG1 overexpression	Esophageal Squamous Cell Carcinoma	NRG1 overexpression	Esophageal Squamous Cell Carcinoma	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3
EGFR mutation	Squamous Cell Carcinoma of Head and Neck	EGFR mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3